On November 10, 2025, the U.S. FDA announced it is initiating removal of the boxed (“black box”) warnings from menopause hormone therapy (MHT) product labeling — specifically removing class-wide references to cardiovascular disease, breast cancer, and “probable dementia.”
What changed (and what didn’t)
What the FDA is removing from boxed warnings (for menopausal hormone therapy labeling):
- Broad, class-wide warning language that implied the same major risks for all estrogen-containing menopausal therapies (and related products), regardless of type/dose/route.
What is NOT being removed:
- The FDA stated it is not seeking to remove the boxed warning about endometrial (uterine) cancer risk for systemic estrogen-alone products. This matters especially for people with a uterus who use estrogen without appropriate uterine protection.
Important detail: The FDA said it is working with manufacturers to update product labels, so the exact timing of label changes depends on the update process.
Why this decision matters so much
For many women, the “black box” warning became a fear trigger, not a nuanced medical explanation. It discouraged people from even discussing options that can be life-changing for symptoms like hot flashes, night sweats, sleep disruption, and vaginal/genitourinary symptoms.
The FDA’s move acknowledges that the old one-size-fits-all warning did not reflect how modern menopause care is actually practiced today — where type of therapy, dose, route (pill vs patch vs vaginal), age, and timing matter.
How women may benefit now
✅ Less stigma + less fear
Women may feel more comfortable asking about treatment options and getting evidence-based counseling rather than being shut down by a scary label.
✅ More individualized, accurate conversations
This change supports a more personalized approach: not “hormones are dangerous,” but “what’s appropriate for you based on your health history and goals.”
✅ Better access to symptom relief
Many experts note that low-dose/local therapies (like vaginal estrogen used for genitourinary symptoms) have long been viewed as having very low systemic absorption, and the old warning could be unnecessarily alarming for those patients.
A crucial reminder: this is not “HRT is risk-free”
This update does not mean hormone therapy is right for everyone, or that risks don’t exist. It means the boxed warning messaging is being revised to better reflect current evidence and benefit–risk considerations.
There’s also active debate about how broadly benefits should be framed beyond symptom treatment, and some experts have criticized the process and public messaging around the change.
What to do next (empowering + practical)
If you’re in perimenopause or menopause and struggling:
- Bring your symptoms to your clinician (don’t minimize them).
- Ask: Which option fits me best — systemic vs local? lowest effective dose? what are my personal risks?
- If you have a uterus, ask specifically about uterine protection if systemic estrogen is being considered.